Artificial Intelligence (AI) in Precision Medicine Market By Component (Hardware, Software, Services); By Technology (Machine Learning, Natural Language Processing, Deep Learning, Computer Vision); By Application (Drug Discovery, Diagnostics, Precision Oncology, Genomics, Clinical Decision Support); By Therapeutic Area (Oncology, Cardiology, Neurology, Immunology); By End User (Pharma & Biotech, Hospitals, Research Institutions); By Region – Growth, Share, Opportunities & Competitive Analysis, 2025 – 2032
Artificial Intelligence (AI) in Precision Medicine Market Overview:
The AI in Precision Medicine Market is projected to grow from USD 3,128.97 million in 2025 to USD 26,376.63 million by 2032, registering a CAGR of 35.60% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2024
Base Year
2025
Forecast Period
2026-2032
Artificial Intelligence (AI) in Precision Medicine Market Size 2025
USD 3,128.97 million
Artificial Intelligence (AI) in Precision Medicine Market, CAGR
35.60%
Artificial Intelligence (AI) in Precision Medicine Market Size 2032
USD 26,376.63 million
AI in Precision Medicine Market Insights:
North America held 44% share in 2025, driven by advanced infrastructure, strong R&D, and early AI adoption; Europe followed with 26%, supported by ethical AI frameworks and health digitization; Asia Pacific accounted for 18%, propelled by healthcare modernization in China, Japan, and South Korea.
Asia Pacific emerged as the fastest-growing region in 2025, supported by national AI strategies, growing genomic databases, and increased investments in digital health ecosystems.
Software accounted for the largest share in the component segment, due to its central role in AI model development, data analytics, and diagnostics integration.
Oncology led the therapeutic area segment in 2025, owing to rising cancer burden, increasing adoption of AI-guided treatment selection, and strong clinical focus on genomics-based therapies.
AI in Precision Medicine Market Drivers:
Rising Demand For Personalized And Data‑Driven Clinical Decision Support Systems
The AI in Precision Medicine Market advances due to rising focus on patient‑specific care models across healthcare systems. Clinicians seek tools that match therapies with genetic and clinical profiles. Artificial intelligence supports faster pattern recognition across complex datasets. Precision care improves outcomes in oncology, cardiology, and rare diseases. Healthcare providers rely on predictive models to reduce trial‑and‑error treatment paths. Hospitals adopt advanced analytics to support early diagnosis accuracy. Research institutions integrate AI for deeper biological insight. Strong clinical value keeps adoption rates high across care settings.
For instance, Tempus AI utilizes its library of more than 40 million de-identified clinical records to provide physicians with AI-generated clinical decision support; in clinical studies using their tumor-normal matched sequencing approach, this technology helped identify incidental pathogenic germline findings in 12% of breast cancer and 15% of ovarian cancer patients.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Expansion Of Genomic And Multi‑Omics Data Across Healthcare Ecosystems
The AI in Precision Medicine Market benefits from rapid growth in genomic, proteomic, and imaging datasets. Sequencing costs decline and increase routine clinical use. AI platforms process high‑volume molecular data with speed and consistency. Researchers apply advanced models to detect disease‑linked biomarkers. Physicians gain clearer insight into therapy response variation. Integrated datasets support better risk stratification across populations. Data interoperability improves collaboration between labs and care providers. Broader data access strengthens long‑term clinical confidence.
For instance, Illumina integrated AI-driven protein structure prediction via PrimateAI-3D, which analyzed 233 primate genomes to identify disease-causing variants; the technology achieved an 87% accuracy rate in predicting pathogenic mutations in human clinical cohorts, significantly reducing the noise in genomic interpretation.
Increased Use Of Artificial Intelligence In Drug Discovery And Clinical Research
The AI in Precision Medicine Market expands through strong use within pharmaceutical research pipelines. Drug developers apply AI to identify novel targets faster. Predictive models improve compound screening accuracy. Clinical researchers rely on AI to select suitable patient cohorts. Trial protocols gain precision through data‑driven insights. Reduced development time improves innovation efficiency. Research sponsors support digital platforms for competitive advantage. This shift strengthens AI relevance across life sciences.
Supportive Healthcare Digitization Policies And Strategic Public‑Private Investments
The AI in Precision Medicine Market gains traction from national digital health initiatives. Governments encourage AI adoption through funding and pilot programs. Healthcare systems modernize infrastructure to support advanced analytics. Public‑private partnerships accelerate technology validation. Regulatory agencies engage with developers to refine approval pathways. Academic centers receive grants for AI‑based medical research. These actions expand trust in clinical AI use. Policy support sustains long‑term market momentum.
AI in Precision Medicine Market Trends:
Integration Of Artificial Intelligence Into Clinical Workflow And Decision Pathways
The AI in Precision Medicine Market shows steady integration within routine clinical processes. Providers embed AI tools into electronic health records. Decision support systems guide therapy selection in real time. Workflow integration reduces manual data review burden. Clinicians prefer platforms with clear interpretability. Seamless interfaces improve physician adoption rates. Hospitals prioritize tools that fit existing systems. This trend reshapes daily clinical practice patterns.
For instance, Mayo Clinic integrated an AI-based screening tool for left ventricular dysfunction into its clinical workflow; in a trial involving 22,647 patients, the AI-enabled pathway increased the diagnosis of low ejection fraction by 32% compared to the standard of care, demonstrating the efficacy of embedding predictive analytics directly into the provider’s decision-making loop.
Growth Of AI‑Enabled Precision Oncology And Rare Disease Applications
The AI in Precision Medicine Market trends toward focused disease‑specific solutions. Precision oncology leads due to complex treatment planning needs. AI models help identify mutation‑driven therapy options. Rare disease diagnosis gains support through pattern recognition. Specialized platforms address limited patient data challenges. Researchers value AI for faster diagnostic confirmation. Clinical teams adopt targeted tools for complex cases. Disease‑centric design strengthens solution relevance.
For instance, Freenome utilizes multiomics and AI to detect early-stage colorectal cancer; in their PREEMPT CRC study, the platform demonstrated a clinical sensitivity of 79.2% for detecting colorectal cancer and 100% for late-stage cases, providing a non-invasive precision tool for early intervention.
Rising Collaboration Between Technology Firms And Healthcare Stakeholders
The AI in Precision Medicine Market reflects growing collaboration across industries. Technology firms partner with hospitals and research institutes. Joint development improves clinical relevance of AI solutions. Healthcare providers offer real‑world data for model training. These partnerships speed product refinement cycles. Shared expertise reduces development risk. Collaborative ecosystems improve innovation quality. This structure supports scalable market growth.
Shift Toward Explainable And Clinically Transparent AI Models
The AI in Precision Medicine Market trends toward transparent algorithm design. Clinicians demand clear reasoning behind AI outputs. Explainable models support trust in treatment decisions. Developers prioritize interpretable frameworks over black‑box systems. Regulatory expectations also favor transparency. Clinical validation strengthens adoption confidence. Transparent AI improves patient communication. This trend aligns technology with medical ethics.
AI in Precision Medicine Market Challenges Analysis:
Data Privacy, Security, And Ethical Concerns Across Healthcare Systems
The AI in Precision Medicine Market faces challenges related to sensitive patient data use. Healthcare data breaches raise trust concerns among stakeholders. Strict privacy regulations increase compliance complexity. Developers must secure large multi‑source datasets. Ethical questions arise around data ownership rights. Cross‑border data sharing faces legal barriers. Patients demand stronger consent frameworks. These issues slow large‑scale deployment efforts.
Limited Standardization And Integration Barriers Within Clinical Infrastructure
The AI in Precision Medicine Market encounters barriers due to fragmented healthcare systems. Data formats vary across hospitals and laboratories. Integration with legacy systems remains complex. Lack of standard clinical benchmarks affects validation. Healthcare staff require training for effective AI use. Resource gaps affect smaller institutions. Inconsistent data quality impacts model performance. These factors restrict uniform adoption.
AI in Precision Medicine Market Opportunities:
Expansion Of AI‑Driven Precision Medicine In Emerging Healthcare Markets
The AI in Precision Medicine Market presents strong opportunities in emerging regions. Healthcare systems modernize digital infrastructure rapidly. Governments invest in advanced diagnostic capabilities. AI supports efficient care delivery in resource‑limited settings. Growing patient populations increase demand for precision tools. Local innovation hubs support tailored solutions. International firms enter new markets through partnerships. These regions offer long‑term growth potential.
Advancement Of Real‑World Evidence And Longitudinal Patient Data Platforms
The AI in Precision Medicine Market gains opportunity from real‑world data integration. Longitudinal datasets improve disease progression analysis. AI models refine treatment personalization over time. Healthcare providers adopt continuous monitoring tools. Real‑world evidence supports clinical and regulatory decisions. Life science firms leverage insights for product development. Data‑driven care pathways improve patient outcomes. This opportunity strengthens future market value.
AI in Precision Medicine Market Segmentation Analysis:
By Component
The AI in Precision Medicine Market is segmented into hardware, software, and services. Software holds the largest share due to its central role in analytics, diagnostics, and decision support. It includes machine learning platforms, predictive algorithms, and cloud-based solutions. Hardware supports processing needs through AI chips and GPUs optimized for medical data. Services, including integration, consulting, and support, are essential for deploying and managing AI platforms across hospitals and biotech labs.
For instance, the NVIDIA IGX Orin 700 hardware platform provides 7 times the AI performance of previous onboard iGPU configurations for real-time medical imaging, while the Clara Holoscan SDK enables developers to deploy AI models that process 4K video at 240 frames per second in surgical video streams with an end-to-end latency of only 10 ms.
By Technology
Machine learning leads the technology segment, driven by its broad application in diagnostics, drug discovery, and clinical decision-making. Natural language processing follows, with strong uptake in interpreting electronic health records and unstructured clinical data. Deep learning enables complex image analysis and genomic pattern recognition. Computer vision shows steady growth, especially in radiology and digital pathology applications, where it supports real-time imaging analysis.
For instance, Google Health’s deep learning model for diabetic retinopathy achieved an area under the receiver operating characteristic curve (AUC) of 0.991, matching the performance of US board-certified ophthalmologists while reducing the diagnostic time per image to less than one second.
By Application
Diagnostics and drug discovery dominate the application landscape. AI enhances speed and accuracy in disease identification and accelerates molecule screening. Precision oncology sees rising adoption, with AI matching therapies to genetic profiles. Genomics applications leverage AI to streamline sequence interpretation. Clinical decision support systems assist in real-time patient care by offering treatment recommendations based on predictive insights.
By Therapeutic Area
Oncology represents the largest therapeutic area due to the complexity of cancer treatment and genomics integration. Cardiology and neurology follow, where AI tools support imaging and early detection. Immunology applications grow through AI-driven analysis of immune response and personalized treatment development.
By End User
Pharma and biotech firms are major adopters, using AI for drug development and biomarker discovery. Hospitals implement AI to improve patient outcomes through faster diagnostics. Research institutions apply AI to expand scientific discovery in genetics, diseases, and treatment optimization.
Segmentation:
By Component
Hardware
Software
Services
By Technology
Machine Learning
Natural Language Processing
Deep Learning
Computer Vision
By Application
Drug Discovery
Diagnostics
Precision Oncology
Genomics
Clinical Decision Support
By Therapeutic Area
Oncology
Cardiology
Neurology
Immunology
By End User
Pharma & Biotech
Hospitals
Research Institutions
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Regional Analysis:
North America
North America accounted for the largest share of the AI in Precision Medicine Market in 2025, holding approximately 44% of the global market. This dominance is supported by early adoption of AI technologies in healthcare, strong funding for genomics research, and robust infrastructure across the United States and Canada. Major players including Microsoft, Google, and IBM operate heavily in this region, strengthening innovation cycles. Government initiatives and regulatory support for digital health continue to boost deployment across hospitals and pharmaceutical companies. Precision oncology and AI-based diagnostics see strong uptake due to high clinical demand. The region remains the center of AI–healthcare convergence.
Europe
Europe held the second-largest market share, contributing around 26% in 2025. Countries such as Germany, the UK, and France lead in terms of AI integration in genomics, diagnostics, and clinical trials. The region benefits from structured health data, ethical AI frameworks, and increasing investments in research collaborations. The European Union’s AI and health digitization strategy continues to enhance interoperability and cross-border precision care projects. Leading academic institutions and AI health start-ups partner to deliver tailored clinical solutions. Public health programs in oncology and neurology create additional opportunities for adoption across public hospitals and labs.
Asia Pacific and Other Regions
Asia Pacific emerged as the fastest-growing region, with a market share of approximately 18% in 2025. China, Japan, and South Korea are key growth drivers, driven by national AI policies, expanding medical datasets, and growing biotech industries. India shows increasing AI activity in genomic testing and digital pathology. Latin America and the Middle East & Africa jointly held 12%, with steady improvements in infrastructure and access to diagnostic technologies. AI pilot programs in oncology and research grants across GCC countries support early adoption. These regions offer long-term expansion potential as digital health ecosystems mature.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
The AI in Precision Medicine Market is highly competitive, with major technology firms and healthcare innovators leading advancements. Companies like NVIDIA, Google, IBM, and Microsoft focus on developing AI platforms that support clinical decision-making, diagnostics, and genomic data interpretation. Pharma players such as AstraZeneca and Sanofi use AI for drug discovery and trial optimization. Emerging companies like Tempus and BioXcel Therapeutics drive innovation through AI-based precision oncology and therapy targeting. It remains dynamic due to continuous investment in AI research, strategic collaborations, and cloud-based infrastructure. Competitive advantage is defined by scalability, clinical validation, and data integration capabilities.
Recent Developments:
In January 2026, Sanofi signed a major autoimmune deal with AI firm Earendil (Helixon) valued at up to $2.56 billion to develop next-generation bispecific antibody candidates discovered through high-throughput AI platforms.
In January 2026, BioXcel Therapeutics Inc. announced plans to submit a supplemental New Drug Application (sNDA) to the FDA for IGALMI™ (BXCL501), seeking approval for the at-home use of its AI-developed treatment for agitation in patients with bipolar disorder or schizophrenia.
In January 2025, NVIDIA collaborated with IQVIA to develop Healthcare-grade AI agents, integrating NVIDIA AI Foundry, NeMo, and DGX Cloud for life sciences workflows from R&D to commercialization.
Report Coverage:
The research report offers an in-depth analysis based on Component, Technology, Application, Therapeutic Area, End User, and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market. [replace all segments in report coverage].
Future Outlook:
AI adoption will expand across hospitals and diagnostics labs, enhancing speed and accuracy in clinical decision-making.
Integration of machine learning into genomic testing will support faster identification of genetic mutations linked to complex diseases.
Pharma companies will increase reliance on AI to reduce drug development timelines and improve patient stratification in clinical trials.
Explainable AI models will gain preference, driving trust and transparency among healthcare professionals and regulators.
Real-time AI-based decision support systems will become standard tools in precision oncology and cardiology care.
Asia Pacific will emerge as a key hub for AI development and deployment, driven by rapid investment in healthcare digitization.
AI-enabled platforms will be increasingly integrated into cloud-based infrastructures, improving scalability and data sharing across systems.
Collaboration between technology firms, academic centers, and medical institutions will accelerate AI innovation and clinical validation.
Regulatory bodies will update frameworks to address safety, ethics, and data protection in AI-driven diagnostics and treatments.
Growth in real-world evidence platforms and population-scale datasets will support longitudinal analysis and next-generation precision medicine applications.
1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope
2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
14.1. Overview
14.2. Bargaining Power of Buyers
14.3. Bargaining Power of Suppliers
14.4. Degree of Competition
14.5. Threat of New Entrants
14.6. Threat of Substitutes
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions
What is the current market size for AI in Precision Medicine Market, and what is its projected size in 2032?
The AI in Precision Medicine Market is valued at USD 3,128.97 million in 2025 and is projected to reach USD 26,376.63 million by 2032, reflecting rapid industry expansion.
At what Compound Annual Growth Rate is the AI in Precision Medicine Market projected to grow between 2025 and 2032?
Between 2025 and 2032, the market is expected to grow at a robust CAGR of 35.60%, supported by technological innovation and increased AI deployment in clinical settings.
Which AI in Precision Medicine Market segment held the largest share in 2025?
The software segment held the largest share in 2025, driven by its widespread use in data analytics, decision support, and machine learning applications.
What are the primary factors fueling the growth of the AI in Precision Medicine Market?
Key drivers include rising demand for personalized care, rapid advancements in genomics, AI integration in drug discovery, and government support for digital health technologies.
Who are the leading companies in the AI in Precision Medicine Market?
Top players include NVIDIA, Microsoft, Alphabet (Google), IBM, AstraZeneca, Sanofi, Tempus, BioXcel Therapeutics, and GE HealthCare, each contributing through innovations and partnerships.
Which region commanded the largest share of the AI in Precision Medicine Market in 2025?
North America commanded the largest share due to its advanced healthcare infrastructure, strong AI R&D investments, and early technology adoption across clinical workflows.
About Author
Sushant Phapale
ICT & Automation Expert
Sushant is an expert in ICT, automation, and electronics with a passion for innovation and market trends.
The 3D Printed Brain Model Market is projected to grow from USD 44.5 million in 2025 to an estimated USD 144.3 million by 2032, with a compound annual growth rate (CAGR) of 18.3% from 2025 to 2032.
The self-service technologies market size was valued at USD 42,148.6 million in 2024 and is anticipated to reach USD 68,199.2 million by 2032, at a CAGR of 6.2% during the forecast period.
The global Biohacking Market size was estimated at USD 29,526.01 million in 2025 and is expected to reach USD 98,319.59 million by 2032, growing at a CAGR of 18.75% from 2025 to 2032.
The global Bioinformatics Market size was estimated at USD 18681.2 million in 2025 and is expected to reach USD 40912.56 million by 2032, growing at a CAGR of 11.85% from 2025 to 2032.
Talent Acquisition and Staffing Technology Market size was valued USD 8,889 Million in 2024 and is anticipated to reach USD 19,192.52 Million by 2032, at a CAGR of 10.1% during the forecast period.
Inkjet Printers Market size was valued at USD 36,400.00 Million in 2018 and increased to USD 42,886.26 Million in 2024, and it is anticipated to reach USD 66,425.93 Million by 2032, growing at a CAGR of 5.71% during the forecast period.
Military Wearables Market size was valued at USD 3,800.00 Million in 2018 and increased to USD 4,167.46 Million in 2024. It is anticipated to reach USD 5,527.89 Million by 2032, at a CAGR of 3.64% during the forecast period.
Mixed Reality Market size was valued at USD 1,950.00 Million in 2018 and USD 5,047.84 Million in 2024, and is anticipated to reach USD 51,937.62 Million by 2032, at a CAGR of 33.97% during the forecast period.
Database Monitoring Software Market size was valued USD 2,389 Million in 2024 and is anticipated to reach USD 7,306.78 Million by 2032, at a CAGR of 15% during the forecast period.
In-display Fingerprint Sensors Market size was valued at USD 1,800.00 Million in 2018 and increased to USD 2,732.34 Million in 2024, and it is anticipated to reach USD 7,332.89 Million by 2032, growing at a CAGR of 13.19% during the forecast period.
The On-Demand Transportation Market size was valued at USD 93,984.94 million in 2024 and is anticipated to reach USD 417,786.73 million by 2032, at a CAGR of 20.5% during the forecast period.
The artificial island construction market was valued at USD 95.92 billion in 2024 and is anticipated to reach USD 139.14 billion by 2032, at a CAGR of 4.76% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$5999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
